Aromatase Inhibitors

Aromatase Inhibitors B. J. A. Furr

Book Details:

Author: B. J. A. Furr
Date: 06 Feb 2008
Publisher: Birkhauser Verlag AG
Language: English
Format: Paperback::189 pages
ISBN10: 3764386924
ISBN13: 9783764386924
Filename: aromatase-inhibitors.pdf
Dimension: 170x 240x 11.18mm::354g

Download Link: Aromatase Inhibitors

Transcript: Hope S. Rugo, MD: The toxicities seen with aromatase inhibitors are fairly well understood now. Many women have joint stiffness We report the case of a 56-year-old woman treated with aromatase inhibitors for a breast cancer. Following one year of such therapy, the patient'presented with Objective and Design: To review the role of aromatase inhibitors (AIs) in the treatment of endometriosis. Conclusion(s): Endometriosis is a common Until recently, tamoxifen, a nonsteroidal antiestrogen, was the mainstay of endocrine treatment of breast cancer. However, new aromatase inhibitors that are Compared with adjuvant tamoxifen alone for five years, do adjuvant aromatase inhibitors (anastrozole, letrozole, or exemestane) alone for five years improve Therein lies the possible role of aromatase inhibitors (AIs) in restoring the normal balance of serum testosterone and estradiol levels for the adequate treatment Abstract. Background: Aromatase inhibitors (AIs) are routinely offered to post-menopausal patients with oestrogen receptor-positive early invasive breast cancer Keywords: anastrozole aromatase inhibitor breast cancer endocrine therapy. Exemestane letrozole postmenopausal lipid tamoxifen. Christos J. Compared with clomiphene (Clomid), are aromatase inhibitors such as letrozole (Femara) effective treatments for subfertile women with Aromatase inhibitors are becom- ing the preferred endocrine therapy, and general internists caring for breast cancer survivors need to be familiar with their use Inhibition of aromatase has been an attractive approach for examining the roles of estrogen biosynthesis in various physiological or pathological processes. Review question: Cochrane authors examined the evidence about aromatase inhibitors (AIs) for subfertile women with polycystic ovary Aromatase inhibitors (AIs) are an important component of adjuvant endocrine therapy in postmenopausal women with estrogen receptor What can you tell postmenopausal ER-positive, early-stage breast cancer patients about aromatase inhibitor therapy? In the comparison of 5 years of aromatase inhibitor versus 5 years of tamoxifen, recurrence RRs favoured aromatase inhibitors significantly The decision to walk away from taking aromatase inhibitors is a choice many women are now making. No longer do they blindly follow the Aromatase inhibitors are an established adjuvant treatment for postmenopausal female breast cancer and have been shown to be more effective than tamoxifen Aromatase inhibitors stop the production of estrogen in postmenopausal women. This means that less estrogen is available to stimulate the growth of hormone-receptor-positive breast cancer cells. When treating early-stage, hormone-receptor-positive breast cancer, aromatase The newer generation aromatase inhibitors (AIs) as a class show efficacy and tolerability benefits over previously established treatments

Download free and read Aromatase Inhibitors eReaders, Kobo, PC, Mac

Avalable for free download to iPad/iPhone/iOS Aromatase Inhibitors